PMID- 33203248
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 16
IP  - 12
DP  - 2020 Dec
TI  - FIRST LINE OF SUBCUTANEOUS ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS: A 
      PROSPECTIVE COHORT STUDY.
PG  - 1217-1225
LID - 10.1080/1744666X.2021.1850271 [doi]
AB  - Objectives: This study aims to evaluate and compare the use of subcutaneous 
      anti-TNF for RA in a Brazilian real-life setting. Methods: A prospective cohort 
      of biological disease-modifying antirheumatic drug (bDMARD)-naive patients 
      treated with adalimumab, etanercept, golimumab, and certolizumab was developed. 
      Medication persistence, disease activity by the Clinical Disease Activity Index 
      (CDAI), functionality by the Health Assessment Questionnaire (HAQ), quality of 
      life by the European Quality of Life 5 Dimensions (EQ-5D), and safety were 
      evaluated at 6 and 12 months. Results: In a total of 327 individuals, 211 (64.5%) 
      were persistent at 12 months. Patients improved after the use of anti-TNF, with a 
      reduction in the mean of CDAI and HAQ, in addition to an increase in the mean of 
      EQ-5D (p < 0.05). The number of patients who achieved the clinical response was 
      114 (34.86%) by CDAI, 212 (64.83%) by HAQ, and 215 (65.75%) by EQ-5D at 
      12 months. There were no statistically significant differences among the drugs (p 
      > 0.05). The anti-TNF was well tolerated. Conclusion: Anti-TNF reduced disease 
      activity, in addition to improving patients' functionality and quality of life. 
      Additional pharmacotherapeutic monitoring can be essential to achieve better 
      results.
FAU - Dos Santos, Jessica Barreto Ribeiro
AU  - Dos Santos JBR
AD  - Health Assessment, Technology, and Economy Group, Center for Exact, Natural and 
      Health Sciences, Federal University of Espirito Santo , Alegre, Brazil.
AD  - Department of Social Pharmacy, College of Pharmacy, Federal University of Minas 
      Gerais , President Antonio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, 
      Brazil.
FAU - da Silva, Michael Ruberson Ribeiro
AU  - da Silva MRR
AUID- ORCID: 0000-0003-2550-7249
AD  - Health Assessment, Technology, and Economy Group, Center for Exact, Natural and 
      Health Sciences, Federal University of Espirito Santo , Alegre, Brazil.
AD  - Department of Social Pharmacy, College of Pharmacy, Federal University of Minas 
      Gerais , President Antonio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, 
      Brazil.
FAU - Kakehasi, Adriana Maria
AU  - Kakehasi AM
AD  - Medicine School, Federal University of Minas Gerais , Belo Horizonte, Brazil.
FAU - Acurcio, Franciscode Assis
AU  - Acurcio FA
AUID- ORCID: 0000-0002-5880-5261
AD  - Department of Social Pharmacy, College of Pharmacy, Federal University of Minas 
      Gerais , President Antonio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, 
      Brazil.
AD  - Medicine School, Federal University of Minas Gerais , Belo Horizonte, Brazil.
FAU - Almeida, Alessandra Maciel
AU  - Almeida AM
AD  - Department of Social Pharmacy, College of Pharmacy, Federal University of Minas 
      Gerais , President Antonio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, 
      Brazil.
AD  - Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Brasil.
FAU - Alves de Oliveira Junior, Haliton
AU  - Alves de Oliveira Junior H
AUID- ORCID: 0000-0002-0289-4947
AD  - Health Technology Assessment Unit, Hospital Alemao Oswaldo Cruz , Sao Paulo, 
      Brazil.
FAU - Pimenta, Pedro Ricardo Komel
AU  - Pimenta PRK
AD  - Department of Social Pharmacy, College of Pharmacy, Federal University of Minas 
      Gerais , President Antonio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, 
      Brazil.
FAU - Alvares-Teodoro, Juliana
AU  - Alvares-Teodoro J
AD  - Department of Social Pharmacy, College of Pharmacy, Federal University of Minas 
      Gerais , President Antonio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, 
      Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201215
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 91X1KLU43E (golimumab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
RN  - UMD07X179E (Certolizumab Pegol)
SB  - IM
MH  - Adalimumab/therapeutic use
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Certolizumab Pegol/therapeutic use
MH  - Etanercept/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Adalimumab
OT  - certolizumab
OT  - etanercept
OT  - golimumab
OT  - observational study
OT  - rheumatoid arthritis
EDAT- 2020/11/19 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/11/18 05:33
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/11/18 05:33 [entrez]
AID - 10.1080/1744666X.2021.1850271 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2020 Dec;16(12):1217-1225. doi: 
      10.1080/1744666X.2021.1850271. Epub 2020 Dec 15.